^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
Excerpt:
...Women aged 18-75 years old; HR positive and HER2 positive (immunohistochemistry or FISH test confirmed)....
Trial ID:
Source:
Title:
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
Excerpt:
...(d) According to ASCOCAP guidelines, tumors are either HR positive or HR negative (ER and PgR negative)....
Trial ID:
More C2 evidence
Source:
Title:
Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial
Excerpt:
...- Presenting with histological(by core needle biopsy or by limited incisional biopsy) proven hormone receptor positive (ER≥10% and/or PR ≥1%), HER2 negative(IHC ≤2+ and/or FISH-) , stage II/ III breast cancer....
Trial ID:
Source:
Title:
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer
Excerpt:
...Pathologically confirmed HER2 positive, hormone receptor-positive patients with locally advanced or metastatic breast cancer: HER2 IHC 3+, or HER2 IHC 2+ and FISH detection gene amplification, ER（estrogen receptor） and/or PR（progesterone receptor） Immunohistochemical staining of more than 10% tumor cells) 2....
Trial ID:
Less C2 evidence
Source:
Title:
Our preliminary results suggested that pyrotinib plus letrozole is feasible for the first-line treatment of patients with HR-positive and HER2-positive MBC
Published date:
06/26/2023
Excerpt:
The CBR was 71.7% (95% CI, 57.7-83.2%), and the objective response rate was 64.2% (95% CI, 49.8-76.9%). The median progression-free survival was 13.7 months (95% CI, 10.7-18.7 months)….Our preliminary results suggested that pyrotinib plus letrozole is feasible for the first-line treatment of patients with HR-positive and HER2-positive MBC...
Secondary therapy:
letrozole
DOI:
10.1186/s12916-023-02943-2
Trial ID:
Source:
Title:
Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial
Published date:
02/15/2022
Excerpt:
Of 14 patients with measurable disease according to RECIST 1.1, seven (50%) achieved objective response. The DCR was 84.6%....The combination of pyrotinib and fulvestrant was convenient and effective with manageable toxicity, which may offer a chemotherapy-free alternative treatment option for patients with HR+/HER2+ metastatic breast cancer.
Secondary therapy:
fulvestrant
DOI:
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-35
Trial ID:
Source:
Title:
Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report
Published date:
09/18/2021
Excerpt:
...a 57-year-old female patient with HER2-positive/HR-positive breast cancer...She was then enrolled in a phase II clinical trial and was treated with pyrotinib plus letrozole, and achieved a durable clinical response.
Secondary therapy:
letrozole
DOI:
10.21037/apm-21-2522
Source:
Title:
Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
Excerpt:
Here, we present a case of a 50-year-old postmenopausal HER2-positive/HR-positive breast cancer patient who received pyrotinib plus letrozole as a first-line treatment following a diagnosis of left axillary lymph node and double lung metastases after modified radical mastectomy for left breast cancer. Two months after administration of combined pyrotinib and letrozole, a complete response (CR) was confirmed by CT scan.
DOI:
10.21037/atm-21-3978
